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http://www.biomedcentral.com/1471-2334/13/197RESEARCH ARTICLE Open AccessImpact of positive chest X-ray findings and blood
cultures on adverse outcomes following
hospitalized pneumococcal lower respiratory tract
infection: a population-based cohort study
Marlene Skovgaard1*, Henrik C Schønheyder2, Thomas Benfield3, Rikke B Nielsen1, Jenny D Knudsen4,
Jette Bangsborg5, Christian Østergaard4, Hans-Christian Slotved6, Helle Bossen Konradsen6, Lotte Lambertsen6
and Reimar W Thomsen1Abstract
Background: Little is known about the clinical presentation and outcome of pneumococcal lower respiratory tract
infection (LRTI) without positive chest X-ray findings and blood cultures. We investigated the prognostic impact of a
pulmonary infiltrate and bacteraemia on the clinical course of hospitalized patients with confirmed pneumococcal
LRTI.
Methods: We studied a population-based multi-centre cohort of 705 adults hospitalized with LRTI and
Streptococcus pneumoniae in LRT specimens or blood: 193 without pulmonary infiltrate or bacteraemia, 250 with
X-ray confirmed pneumonia, and 262 with bacteraemia. We compared adverse outcomes in the three groups and
used multiple regression analyses to adjust for differences in age, sex, comorbidity, and lifestyle factors.
Results: Patients with no infiltrate and no bacteraemia were of similar age but had more comorbidity than the
other groups (Charlson index score ≥1: no infiltrate and no bacteraemia 81% vs. infiltrate without bacteraemia 72%
vs. bacteraemia 61%), smoked more tobacco, and had more respiratory symptoms. In contrast, patients with a
pulmonary infiltrate or bacteraemia had more inflammation (median C-reactive protein: no infiltrate and no
bacteraemia 82 mg/L vs. infiltrate without bacteraemia 163 mg/L vs. bacteraemia 316 mg/L) and higher acute
disease severity scores. All adverse outcomes increased from patients with no infiltrate and no bacteraemia to those
with an infiltrate and to those with bacteraemia: Length of hospital stay (5 vs. 6 vs. 8 days); intensive care admission
(7% vs. 20% vs. 23%); pulmonary complications (1% vs. 5% vs. 14%); and 30-day mortality (5% vs. 11% vs. 21%).
Compared with patients with no infiltrate and no bacteraemia, the adjusted 30-day mortality rate ratio was
1.9 (95% confidence interval (CI) 0.9-4.1) in patients with an infiltrate without bacteraemia and 4.1 (95% CI 2.0-8.5) in
bacteraemia patients. Adjustment for acute disease severity and inflammatory markers weakened these associations.
Conclusions: Hospitalization with confirmed pneumococcal LRTI is associated with substantial morbidity and
mortality even without positive chest X-ray findings and blood cultures. Still, there is a clinically important outcome
gradient from LRTI patients with pneumococcal isolation only to those with detected pulmonary infiltrate or
bacteraemia which is partly mediated by higher acute disease severity and inflammation.
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Streptococcus pneumoniae is the most frequently identi-
fied pathogen associated with community acquired
pneumonia (CAP) [1] and bacterial lower respiratory
tract infection (LRTI) [2]. S. pneumoniae accounts for an
estimated 30% of all hospitalized CAP episodes [3] and
for up to half of CAP episodes where aetiology is known
[4-8]. The burden of pneumococcal LRTI is likely to in-
crease in Western populations due to the increasing
number of elderly citizens with chronic diseases. A re-
cent American study estimated that hospitalizations for
pneumococcal pneumonia will increase by 96% from 2004
to 2040, with an amplified annual cost of $2.5 billion in
the USA [9]. Thirty-day mortality following hospitalization
with pneumococcal pneumonia is 5-13% for non-
bacteraemic episodes [10,11], 16-21% for bacteraemic
pneumococcal pneumonia [10-13], and 15-37% for epi-
sodes in the ICU [14,15].
In-hospital diagnostics usually include chest X-ray
and blood culturing, but hospitalized pneumococcal
LRTI episodes do not always present themselves with
bacteraemia or a pulmonary infiltrate. Presence of bac-
teraemia or a pulmonary infiltrate without bacteraemia
in patients with pneumococcal LRTI may be associ-
ated with a worse prognosis due to higher acute dis-
ease severity, inflammation and hypoxaemia [16], but
data on this association are limited. A few studies of
limited size have compared the prognosis of pneumo-
coccal pneumonia and bacteraemia respectively, with
conflicting results [10,14,17,18]. Others compared ‘all-
cause’ LRTI patients with and without pulmonary
infiltrates, and showed a statistically non-significantly
increased mortality associated with the presence of an
infiltrate [19-21]. However, little is known about the
presentation and outcome of hospitalized pneumo-
coccal LRTI with no pulmonary infiltrate and no
bacteraemia.
To improve clinical surveillance and treatment of
pneumococcal infections, it is important to improve
our understanding of the disease pathogenesis and the
clinical course of the entire spectrum of pneumococcal
LRTI among hospitalized patients. This includes clarify-
ing whether X-ray findings and blood cultures add extra
information on the clinical course and consequences
of confirmed pneumococcal infection, or if they are
merely of diagnostic value or of importance to re-
searchers. We therefore undertook a population-based
study covering one-third of Denmark’s population to
examine clinical presentation and outcomes among
three manifestation groups of pneumococcal LRTI, hy-
pothesizing a clinical outcome gradient from patients
with no infiltrate and no bacteraemia to those with an
infiltrate without bacteraemia to those with detected
bacteraemia.Methods
Study population
From January 1st 2011 to December 31st 2011 a popula-
tion based cohort was created, including patients over
the age of 15 years with a pneumococcal isolate from
the lower respiratory tract and/or the blood diagnosed
by one of three Danish Departments of Clinical Micro-
biology at Aalborg Hospital, Herlev Hospital and
Hvidovre Hospital, respectively. The total uptake area
for the three departments was approximately two million
people (~35% of Denmark’s 5.6 million inhabitants), pro-
viding microbiological services for patients from 15 hos-
pitals and over 1000 general practitioners in that area.
A detailed chart review was done for 1,169 episodes
with a positive culture for S. pneumoniae, to access in-
formation on LRTI diagnosis and its manifestation (site
of pneumococcal isolation and chest X-ray findings), pa-
tient and clinical characteristics, and outcomes. Because
the focus of our study was prognosis following incident
hospitalization with acute pneumococcal LRTI, we ex-
cluded episodes treated in the primary care setting only
(n=327), repeated hospitalizations with pneumococcal
LRTI during 2011 (n=34), and patients with no LRT
focus, i.e.; neither an acute LRTI discharge diagnosis
(ICD10 codes: J13, J18.0, J18.1, J18.2, J18.8, J18.9, J20,
J20.2, J20.9, J22, J44.0, J44.1) nor any new or worsened
LRTI symptoms (cough, sputum production, dyspnoea,
chest pain), nor any new pulmonary infiltrate (n=63).
Among patients with no pulmonary infiltrate and no
pneumococcal bacteraemia, we further excluded patients
without elevated inflammatory markers (C-reactive pro-
tein (CRP) >50 mg/L and/or leukocyte count >8.8*109/L)
and at least one LRTI symptom (n= 35), to maximise the
likelihood of acute pneumococcal infection and not
merely colonization. Patients without a valid Danish Civil
Registration Number (i.e. individuals not living perman-
ently in Denmark) were also excluded (n= 5). Thus, the
final study cohort consisted of 705 hospitalized patients
aged 15 years or older with acute LRTI and a pneumococ-
cal isolate from the LRT (n=443) and/or blood (n=262)
(see flow chart in Additional file 1).
Exposure: pneumococcal LRTI manifestation
We divided our patient cohort into three predefined
pneumococcal LRTI manifestation groups, based on
pneumococcal isolation site and chest X-ray findings:
pneumococcal bacteraemia, pulmonary infiltrate without
bacteraemia, and neither pulmonary infiltrate nor bac-
teraemia. Patients with pneumococcal isolates from both
blood and LRT (n=55) were included in the bacteraemia
group. Patients from whom no blood culture had been
obtained within four days from the LRT sample (n=152)
or who had no chest X-ray taken within seven days from
the index date (n=71) were considered to have no
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was defined as the LRT or blood specimen sample date.
For the 55 patients (8%) who had both a positive blood
culture and a positive LRT sample, we defined the index
date as that closest to the date of chest X-ray or, in the
absence of an X-ray (n=6), as the date of the first posi-
tive sample. X-ray findings were recorded from the writ-
ten interpretation provided by the radiologist and/or
from the medical records.
We registered results for all sputum Gram stains, cul-
tures of LRT samples, blood cultures, and pleural fluid
cultures as obtained at the managing physician’s discre-
tion (i.e., when infection was suspected). The vast major-
ity of the LRT samples were sputum (80%), 15% of
samples were obtained by blind endotracheal suction,
whereas the remaining 5% were BAL or pleural fluid
(see Additional file 2). The methods for performing each
of these tests were those in place at the participating in-
stitutions, however, at all departments sputum was
processed for culture only if it contained a significant
number of leukocytes (>25 per low power field) with or
without columnar epithelial cells, and/or no or few squa-
mous epithelial cells (<10 per low power field) [22,23].
Blood samples were cultured for at least five days before
declared negative. A sample was only regarded as posi-
tive for pneumococci if a culture isolate was available.
Identification of S. pneumoniae was done with standard
methods including Gram stain, detection of capsular
antigen by latex agglutination or quelling test as well as
optochin test or bile solubility test [24,25].
Preadmission patient and clinical characteristics
We ascertained important preadmission patient charac-
teristics that may be associated with both the type of
pneumococcal LRTI manifestation and the patient’s risk
of death, including age, sex, comorbidity, smoking, and
alcohol overuse [12,13,26-29]. We also recorded body
mass index (BMI), travel history, housing, and pneumo-
coccal vaccination status if noted in the medical records.
To account for comorbidity as a potential confounder,
Charlson’s comorbidity index scores were calculated for
each patient. The Charlson index is a weighted index
that includes 19 different disease categories and takes
into account the number and the seriousness of comor-
bid disease [12,13,30]. Data on each patient’s complete
hospitalization history of co-existing diseases was
obtained from The Danish National Registry of Patients
(DNRP) using linkage by unique civil registration num-
bers. The DNRP includes all patient admissions to
Danish hospitals since 1977 and all hospital outpatient
visits since 1995 [31]. Three comorbidity levels were de-
fined: low (score of 0), medium (1–2), and high (≥3).
We also examined clinical presentation and acute
symptoms within 24 hours of the index date. Weascertained presence of acute respiratory symptoms
(dyspnoea, cough, sputum production or chest pain),
plasma glucose level, CRP level, leukocyte count, body
temperature, mean arterial blood pressure (MAP), pe-
ripheral oxygen saturation (SAT), and two disease se-
verity scores; the CURB-65 score [32] and the Pitt
score [33].
Outcomes
The primary endpoint was all-cause 30-day mortality
following the index date. Complete follow-up for morta-
lity was ensured by linkage to the Danish Civil Registra-
tion System (CRS), which encompasses all residents who
live – or have lived – in Denmark since 1968 [34].
Secondary endpoints were length of hospital stay
(LOS), admission to an intensive care unit (ICU), and
pulmonary complications (ICD-10 codes of pleural
effusion J90 and J91, pleural drainage KGAA96,
KGAA97, KGAA10, empyema J86, lung abscess J85, or
ARDS J80.9). If a patient was discharged and readmit-
ted again within 48 hours, total LOS was calculated
from the date of admission to the day of the latest
discharge.
Statistical analyses
For the three LRTI manifestation groups, we compared
the distribution of baseline and clinical characteristics
and calculated prevalence proportion ratios with 95%
confidence intervals (CIs) and medians with interquartile
range (IQR) as displayed in Tables 1 and 2. We exam-
ined the association between LRTI manifestation group
and the risk of intensive care admission and pulmonary
complications by Poisson regression. We used linear re-
gression to examine the ratios of the means of LOS in
the three groups. For mortality analyses we constructed
Kaplan-Meier survival curves and computed cumulative
mortality. Cox’s regression was used to compute 30-day
mortality rate ratio (MRR) estimates with 95% CIs com-
paring mortality for the three manifestation groups. The
regression analyses were used to control for predefined
major potential confounders: sex, age (as a continuous
variable), level of comorbidity, current or former smok-
ing, and excessive alcohol consumption (>7 units per
week for women and >14 units per week for men). We
also performed an additional adjusted analysis to assess
whether differences in acute disease severity and inflam-
matory markers accounted for differences in 30-day
mortality.
We analysed data using Stata software (version 11.2;
StataCorp, College Station, TX, USA). The National
Health Board (record no. 7-604-04-2/332) and the Danish
Data Protection Agency (record no. 2011-41-6426) ap-
proved this study.
Table 1 Preadmission baseline characteristics of 705 patients hospitalized for pneumococcal LRTI, according to
manifestation group
Characteristics No infiltrate and no bacteraemia patients Infiltrate without bacteraemia patients Bacteraemia patients
n (%) a PR (95% CI) n (%) a PR (95% CI) n (%) a PR (95% CI)
All patients 193 (100) 250 (100) 262 (100)
Age (years)
Median 68 (59–76) 69 (57–79) 68 (57–80)
15-49 22 (11) 1.0 (ref.) 38 (15) 1.3 (0.8-2.2) 47 (18) 1.6 (1.0-2.5)
50-74 116 (60) 1.0 (ref.) 129 (52) 0.9 (0.7-1.0) 128 (49) 0.8 (0.7-1.0)
≥75 55 (29) 1.0 (ref.) 83 (33) 1.2 (0.9-1.5) 87 (33) 1.2 (0.9-1.5)
Sex
Women 83 (43) 1.0 (ref.) 90 (36) 0.8 (0.7-1.1) 123 (47) 1.1 (0.9-1.3)
Men 110 (57) 1.0 (ref.) 160 (64) 1.1 (1.0-1.3) 139 (53) 0.9 (0.8-1.1)
Charlson comorbidity Index
Index low (0) 36 (19) 1.0 (ref.) 70 (28) 1.5 (1.1-2.1) 101 (39) 2.1 (1.5-2.9)
Index medium (1–2) 96 (50) 1.0 (ref.) 92 (37) 0.7 (0.6-0.9) 81 (31) 0.6 (0.5-0.8)
Index high (≥3) 61 (32) 1.0 (ref.) 88 (35) 1.1 (0.9-1.5) 80 (31) 1.0 (0.7-1.3)
Chronic pulmonary disease b 112 (58) 1.0 (ref.) 114 (46) 0.8 (0.7-0.9) 58 (22) 0.4 (0.3-0.5)
Chronic heart disease c 26 (13) 1.0 (ref.) 35 (14) 1.0 (0.6-1.7) 35 (13) 1.0 (0.6-1.6)
BMI (median) 23.5 (20.0-27.4) 23.3 (21.0-26.3) 23.6 (21.9-26.7)
Smoking 112 (58) 1.0 (ref.) 114 (46) 0.8 (0.7-0.9) 58 (22) 0.4 (0.3-0.5)
Yes, currently 106 (58) 1.0 (ref.) 122 (53) 0.9 (0.8-1.1) 99 (43) 0.7 (0.6-0.9)
No, former 57 (31) 1.0 (ref.) 69 (30) 1.2 (0.6-2.4) 66 (29) 3.1 (1.7-5.7)
No, never 12 (7) 1.0 (ref.) 18 (8) 1.0 (0.7-1.3) 47 (20) 0.9 (0.7-1.2)
No, unknown 7 (4) 1.0 (ref.) 21 (9) 2.4 (1.0-5.5) 18 (8) 2.0 (0.8-4.8)
Alcohol
>7/14 per week d 31 (18) 1.0 (ref.) 60 (27) 1.5 (1.0-1.7) 48 (23) 1.2 (0.8-1.9)
≤7/14 per week d 68 (40) 1.0 (ref.) 89 (40) 1.0 (0.8-1.3) 69 (32) 0.8 (0.6-1.1)
Never 71 (42) 1.0 (ref.) 76 (34) 0.8 (0.6-1.0) 96 (45) 1.1 (0.9-1.4)
Employment
Employed 18 (12) 1.0 (ref.) 24 (13) 1.0 (0.6-1.8) 47 (24) 1.9 (1.2-3.2)
Unemployed 7 (5) 1.0 (ref.) 10 (5) 1.1 (0.4-2.9) 5 (3) 0.5 (0.2-1.6)
Pension 117 (81) 1.0 (ref.) 142 (76) 0.9 (0.8-1.1) 140 (70) 0.9 (0.8-1.0)
Other e 3 (2) 1.0 (ref.) 10 (5) 2.6 (0.7-9.3) 6 (3) 1.5 (0.4-5.8)
Housing
Own house/apartment 166 (94) 1.0 (ref.) 207 (89) 1.0 (0.9-1.0) 213 (93) 1.0 (0.9-1.0)
Institution 9 (5) 1.0 (ref.) 20 (9) 1.7 (0.8-3.6) 14 (6) 1.2 (0.5-2.7)
Homeless 2 (1) 1.0 (ref.) 5 (2) 1.9 (0.4-9.7) 1 (0) 0.4 (0.0-4.2)
Travel history f 7 (4) 1.0 (ref.) 7 (3) 0.8 (0.3-2.2) 7 (3) 0.7 (0.3-2.1)
Vaccination
Influenza vaccine 2 (1) 1.0 (ref.) 1 (0) NA 0 (0) NA
Pneumococcal vaccine 0 (0) 1.0 (ref.) 1 (0) NA 0 (0) NA
LRTI, lower respiratory tract infection; PR, prevalence ratio; CI, confidence interval; ref, reference; NA, not applicable; BMI, Body mass index.
a Data are n (% of everyone we have data for) or median (interquartile range).
b Chronic pulmonary disease: ICD-8: 490–493, 515–518. ICD-10: DJ40-DJ47, DJ60-DJ67, DJ68.4, DJ70.1, DJ70.3, DJ84.1, DJ92.0, DJ96.1, DJ98.2, DJ98.3.
c Congestive heart failure: ICD-8: 427.09, 427.10, 427.11, 427.19, 428.99, 782.49. ICD-10: DI50, DI11.0, DI13.0, DI13.2.
d 7 units of alcohol for women and 14 for men per week.
e “Other” employment covers: students, maternity leave, and rehabilitation support.
f Travel within three month prior to the index date.
Results were available for >87% except for BMI (could be calculated for 20-26% of patients), employment (available for 74-75%), alcohol use (81-90%) and
vaccination (only noted if defiantly positive).
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Table 2 Clinical characteristics +/−24 hours from the index date according to LRTI manifestation group
Characteristics No infiltrate and no bacteraemia
patients
Infiltrate without bacteraemia
patients
Bacteraemia patients
n (%) a PR (95% CI) n (%) a PR (95% CI) n (%) a PR (95% CI)
Medical ward 188 (97) 1.0 (ref.) 229 (92) 0.9 (0.9-1.0) 249 (95) 1.0 (0.9-1.0)
Community acquired b 167 (87) 1.0 (ref.) 217 (87) 1.0 (0.9-1.1) 242 (92) 1.1 (1.0-1.1)
Antibiotics 155 (80) 1.0 (ref.) 235 (94) 1.2 (1.1-1.3) 260 (99) 1.2 (1.2-1.3)
Aetiology
Pneumococcal only 137 (71) 1.0 (ref.) 178 (71) 1.0 (0.9-1.1) 219 (84) 1.2 (1.1-1.3)
Pneumococcal mixed c 56 (29) 1.0 (ref.) 72 (29) 1.0 (0.7-1.3) 43 (16) 0.6 (0.4-0.8)
Respiratory symptoms d
0 0 (0) 1.0 (ref.) 20 (8) NA 35 (13) NA
1 33 (17) 1.0 (ref.) 25 (10) 0.6 (0.4-0.9) 56 (21) 1.3 (0.8-1.8)
2 44 (23) 1.0 (ref.) 59 (24) 1.0 (0.7-1.5) 79 (30) 1.3 (1.0-1.8)
≥3 116 (60) 1.0 (ref.) 146 (58) 1.0 (0.8-1.1) 92 (36) 0.6 (0.5-0.7)
Oxygen saturation
(peripheral)
94 (91–96) 92 (88–95) 93 (89–95)
Temperature ≥38.5°C 35 (20) 1.0 (ref.) 86 (37) 1.8 (1.3-2.6) 126 (50) 2.5 (1.8-3.4)
MAP (mmHg) 91 (78–103) 88 (73–99) 80 (72–97)
CURB65 ≥2 68 (35) 1.0 (ref.) 121 (48) 1.4 (1.1-1.7) 160 (61) 1.7 (1.4-2.1)
PITT ≥4 12 (6) 1.0 (ref.) 28 (11) 1.8 (0.9-3.4) 41 (16) 2.5 (1.4-4.7)
CRP (mg/L)
Median 82 (36–140) 163 (70–246) 316 (219–404)
<50 54 (31) 1.0 (ref.) 41 (17) 0.6 (0.4-0.8) 8 (3) 0.1 (0.1-0.2)
50-99 46 (26) 1.0 (ref.) 36 (15) 0.6 (0.4-0.9) 14 (6) 0.2 (0.1-0.4)
100-199 52 (30) 1.0 (ref.) 68 (29) 1.0 (0.7-1.3) 32 (13) 0.4 (0.3-0.6)
≥200 24 (14) 1.0 (ref.) 91 (39) 2.8 (1.9-4.2) 196 (78) 5.7 (3.9-8.4)
Leukocyte count (109/L)
Median 14 (11–17) 14 (11–19) 17 (12–23)
<3,5 3 (1) 1.0 (ref.) 8 (3) 6.1 (0.8-48.0) 17 (7) 12.2 (1.6-90.5)
3.5-8.7 17 (10) 1.0 (ref.) 25 (11) 1.1 (0.6-2.0) 22 (9) 0.9 (0.5-1.7)
8.8-14.9 90 (51) 1.0 (ref.) 98 (42) 0.8 (0.7-1.0) 57 (23) 0.5 (0.3-0.6)
≥15.0 70 (40) 1.0 (ref.) 103 (44) 1.1 (0.9-1.4) 153 (61) 1.6 (1.3-1.9)
LRTI, lower respiratory tract infection; PR, prevalence ratio; CI, confidence interval; ref, reference; NA, not applicable; MAP, Mean Arterial Pressure; CURB65,
Confusion Urea Respiration-frequency Blood-pressure 65years; PITT , Pitt’s bacteraemia severity score; CRP, C-reactive protein.
a In the n (%) columns data are either n (% of everyone we have data for) or median (interquartile range).
b Community acquired infections are defined as having the index date ≤ 2 days form admission.
c Mixed aetiology is defined as finding of other pathogenic bacteria than pneumococci in either blood or LRT specimen.
d Respiratory symptoms include dyspnoea, cough, sputum production and chest pain.
Results were available for >87% of the patients except the individual measures that constitute the CURB65 score (58-99% worst for respiratory frequency and
carbamide). CURB65 and PITT were calculated out of everyone, though at least one measure pr. patient was missing in 60-62% of patients for the CURB65 score
and 9-18% for the PITT score. Missing valuables were regarded as “no”. Sums were thus calculated as “minimums”.
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Descriptive data
Of the 705 adult in-patients with confirmed acute pneumo-
coccal LRTI, 262 (37%) had pneumococcal bacteraemia. Of
the 443 without bacteraemia, 250 (56%) had X-ray con-
firmed pneumonia and 193 (44%) had neither bacteraemia
nor a pulmonary infiltrate. The age was similar between
groups: 68 years (IQR 59–76) among patients with no infil-
trate and no bacteraemia, 69 years (57–79) among patientswith an infiltrate and no bacteraemia and 68 years (57–80)
for bacteraemia patients. Sex, BMI, alcohol intake, housing,
travel history, and vaccination status did not differ materi-
ally by clinical manifestation of pneumococcal disease
(Table 1). Patients with pneumococcal LRTI with no infil-
trate and no bacteraemia had more chronic pulmonary dis-
ease and more overall comorbidity than the other groups
(Charlson index score ≥1: no infiltrate and no bacteraemia
81% vs. infiltrate without bacteraemia 72% vs. bacteraemia
Figure 1 Kaplan-Meier survival curves for patients hospitalized with
pneumococcal LRTI according to manifestation group. The numbers
at risk represent the number of patients still at risk of death at a given
time during the follow-up period. LRTI, lower respiratory tract infection.
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review and discharge diagnoses, patients with no infiltrate
and no bacteraemia often had acute bronchitis without
pneumonia, exacerbation of chronic obstructive lung
disease, or suspected clinical pneumonia where the tim-
ing of the chest X-ray was suboptimal compared with
the time of peak clinical LRTI symptoms (see Additional
file 3).
Table 2 provides data on clinical characteristics within 24
hours from the index date. The vast majority of patients
were acutely admitted to a medical ward (92-97%), had
community acquired infection (87-92%), and had no add-
itional bacterial pathogens in their blood or lower airways
(71-84%). Patients with no infiltrate and no bacteraemia
were less likely to receive antibiotic treatment on the
index date of obtaining the sample or have a fever, while
they had more respiratory symptoms than the bacter-
aemia patients. The most prevalent symptom for all
groups was cough (65-80%, lowest for the bacteraemia
group). Eight per cent of patients in the no infiltrate
and no bacteraemia group, versus 1% in both the infil-
trate without bacteraemia and the bacteraemia groups
did not receive antibiotics at any point of time during
hospitalization. CRP rose from 82 mg/L in the no infiltrate
and no bacteraemia group to 163 in the infiltrate without
bacteraemia group and 316 in the bacteraemia group,
whereas counts of leukocytes rose from 14*109/L (IQR:
11–17) to 14 (11–19) to 17 (12–23), respectively (Table 2).
Stratification by age revealed similar successive in-
creases in CRP and leukocyte counts across LRTI mani-
festations in all age groups (see Additional file 4).
Data on plasma glucose levels were available for 60-71%
of the patients and showed that the fraction of patients
with glucose above 11.1 mmol/L rose from 10% in the
no infiltrate and no bacteraemia group to 15% and 18%
in the infiltrate without bacteraemia and bacteraemia
groups, respectively. Of the patients with no infiltrate
and no bacteraemia, 55% received a discharge diagnosis
of acute LRTI, compared with 72% and 76% of patients
with infiltrate but no bacteraemia and bacteraemia, re-
spectively (see Additional file 3).
Pneumococcal LRTI manifestation and 30-day mortality
Thirty-day mortality among patients with no infiltrate and
no bacteraemia reached 5%, as compared with 11% and
21% for patients with an infiltrate without bacteraemia and
patients with bacteraemia, respectively. When dividing the
bacteraemia group further into those with (202/262=77%)
and without (60/262=23%) a pulmonary infiltrate, mortal-
ity was highest for bacteraemia without an infiltrate (28 vs.
18%). As seen from Figure 1, patients with bacteraemia
had higher mortality than the other patients from the first
days of observation; whereas the two patient groups with-
out bacteraemia had rather similar mortality during thefirst week after which a difference between the two be-
came more apparent. Compared with patients with no in-
filtrate and no bacteraemia, the adjusted 30-day MRR was
1.9 (95% CI 0.9-4.1) in patients with an infiltrate without
bacteraemia and 4.1 (2.0-8.5) in bacteraemia patients
(Table 3). Supplementary analyses showed adjusted 7-day
MRRs of 1.1 (0.4-3.1) for the infiltrate without bacteraemia
group and 4.0 (1.7-9.9) for the bacteraemia group, respect-
ively, and 8-30-day MRRs of 3.5 (1.0-12.5) and 4.2 (1.2-
14.8). A similar 30-day mortality gradient from patients
with no infiltrate and no bacteraemia, over those with infil-
trate without bacteraemia, to bacteraemia patients was ob-
served for males and females, and in different patient
groups according to age and comorbidity level (Table 3).
Stratification for level of CRP revealed that the association
between LRTI manifestation group and mortality weak-
ened with rising CRP, i.e., the prognostic impact of pul-
monary infiltrate and bacteraemia was less pronounced
among patients who all had high CRP levels (Table 3). The
additional adjusted analysis showed that further inclusion
of the acute disease markers CRP, leukocyte count, MAP
and SAT in the regression model reduced the 30-day MRR
for infiltrate without bacteraemia and bacteraemia patients
to 1.6 (0.7-3.6) and 2.9 (1.2-7.0) respectively.
Pneumococcal LRTI manifestation and length of stay, ICU
admission and pulmonary complications
Table 4 provides data on secondary outcomes. Median
length of stay was 5 (IQR 2–9), 6 (4–16) and 8 (4–19)
days for patients with no infiltrate and no bacteraemia,
infiltrate without bacteraemia, and bacteraemia in that
order. Stratification by age groups and level of comor-
bidity did not reveal any major differences; and similar
Table 3 30-day-mortality according to LRTI manifestation group overall and stratified by subgroups
Prognostic factor No infiltrate and no bacteraemia patients Infiltrate without bacteraemia patients Bacteraemia patients
n (%) Crude MRR
(95 % CI) a
Adjusted MRR
(95% CI) a,b
n (%) Crude MRR
(95% CI) a
Adjusted MRR
(95% CI) a,b
n (%) Crude MRR
(95 % CI) a
Adjusted MRR
(95% CI) a,b
All patients 9 (5) 1.0 (ref.) 1.0 (ref.) 27 (11) 2.4 (1.1-5.0) 1.9 (0.9-4.1) 54 (21) 4.8 (2.4-9.6) 4.1 (2.0-8.5)
Age group (years)
15-49 0 (0) 1.0 (ref.) 1.0 (ref.) 3 (8) NA NA 2 (4) NA NA
50-74 5 (4) 1.0 (ref.) 1.0 (ref.) 13 (10) 2.3 (0.8-6.6) 2.1 (0.7-6.0) 28 (22) 5.5 (2.1-14.3) 5.2 (2.0-13.8)
≥75 4 (7) 1.0 (ref.) 1.0 (ref.) 11 (13) 1.8 (0.6-5.8) 1.6 (0.5-5.3) 24 (28) 4.1 (1.4-11.9) 3.3 (1.1-9.9)
Sex
Women 3 (4) 1.0 (ref.) 1.0 (ref.) 7 (8) 2.2 (0.6-8.3) 2.2 (0.6-9.0) 20 (16) 4.7 (1.4-15.9) 4.3 (1.2-15.6)
Men 6 (5) 1.0 (ref.) 1.0 (ref.) 20 (13) 2.3 (0.9-5.8) 1.8 (0.7-4.5) 34 (24) 4.9 (2.1-11.7) 4.2 (1.7-10.3)
Comorbidity index
Index low (0) 1 (3) 1.0 (ref.) 1.0 (ref.) 4 (6) 2.1 (0.2-18.6) 1.5 (0.2-14.7) 15 (15) 5.7 (0.7-42.8) 4.1 (0.5-32.5)
Index medium (1–2) 2 (2) 1.0 (ref.) 1.0 (ref.) 13 (14) 7.1 (1.6-31.5) 5.8 (1.3-26.2) 14 (17) 8.9 (2.0-39.1) 8.1 (1.8-36.8)
Index high (≥3) 5 (9) 1.0 (ref.) 1.0 (ref.) 10 (12) 1.1 (0.4-3.1) 0.8 (0.3-2.3) 25 (31) 3.5 (1.4-8.5) 2.9 (1.2-7.3)
Chronic pulmonary disease c
Yes 6 (5) 1.0 (ref.) 1.0 (ref.) 12 (11) 2.0 (0.7-5.3) 1.3 (0.5-3.5) 14 (24) 4.8 (1.9-12.6) 3.8 (1.4-10.3)
No 3 (4) 1.0 (ref.) 1.0 (ref.) 15 (11) 3.1 (0.9-10.5) 2.6 (0.7-9.4) 40 (20) 5.7 (1.8-18.6) 4.5 (1.4-14.9)
CRP (mg/L)
<100 1 (1) 1.0 (ref.) 1.0 (ref.) 8 (10) 10.7 (1.3-85.8) 11.3 (1.4-95.4) 7 (32) 35.6 (4.4-290) 27.6 (2.8-267)
100-199 3 (6) 1.0 (ref.) 1.0 (ref.) 6 (9) 1.5 (0.4-6.1) 1.1 (0.2-5.3) 4 (13) 2.2 (0.5-9.6) 2.8 (0.5-15.7)
≥200 4 (17) 1.0 (ref.) 1.0 (ref.) 12 (13) 0.8 (0.3-2.4) 0.6 (0.2-2.1) 41 (21) 1.3 (0.5-3.6) 1.3 (0.5-3.6)
Leukocyte count (109/L)
<3,5 1 (100) 1.0 (ref.) 1.0 (ref.) 3 (38) 0.1 (0.0-2.1) NA 8 (47) 0.3 (0.0-2.3) 0.2 (0.0-3.4)
3.5-8.7 0 (0) 1.0 (ref.) 1.0 (ref.) 1 (4) NA NA 7 (32) NA NA
8.8-14.9 3 (3) 1.0 (ref.) 1.0 (ref.) 12 (12) 3.7 (1.1-13.3) 2.8 (0.7-10.4) 8 (14) 4.4 (1.2-16.4) 2.7 (0.7-11.6)
≥15.0 4 (6) 1.0 (ref.) 1.0 (ref.) 10 (10) 1.7 (0.5-5.4) 1.3 (0.4-4.4) 29 (19) 3.5 (1.2-10.0) 3.2 (1.1-9.5)
LRTI, lower respiratory tract infection; MRR, mortality rate ratio; CI, confidence interval; ref, reference; NA, not applicable because of too few events to calculate MRRs; CRP, C-reactive protein.
a MRR estimates are calculated using cox-regression.
b MRR estimates are adjusted for age, sex, comorbidity, smoking, and alcohol intake (except when stratified by variable).
c Chronic pulmonary disease: ICD-8: 490–493, 515–518. ICD-10: DJ40-DJ47, DJ60-DJ67, DJ68.4, DJ70.1, DJ70.3, DJ84.1, DJ92.0, DJ96.1, DJ98.2, DJ98.3.
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Table 4 Length of stay, risk of ICU admission and pulmonary complications according to LRTI manifestation group
No infiltrate and no bacteraemia
patients
Infiltrate without bacteraemia
patients
Bacteraemia patients
n (%) a Crude RR b Adjusted RR c n (%) a Crude RR b Adjusted RR c n (%) a Crude RR b Adjusted RR c
LOS (days) 5 (2–9) 1.0 (ref.) 1.0 (ref.) 6 (4–16) 1.6 (1.3-2.0) 1.5 (1.2-1.9) 8 (4–19) 2.0 (1.6-2.4) 2.1 (1.7-2.6)
ICU admission 14 (7) 1.0 (ref.) 1.0 (ref.) 51 (20) 2.8 (1.6-5.0) 2.4 (1.4-4.1) 60 (23) 3.2 (1.8-5.5) 3.1 (1.8-5.5)
Pulmonary complications d 2 (1) 1.0 (ref.) 1.0 (ref.) 12 (5) 4.6 (1.0-20.5) 4.6 (1.0-21.4) 36 (14) 13.3 (3.2-54.5) 12.6 (2.9-53.8)
LRTI, lower respiratory tract infection; RR, relative risk; LOS, length of stay; ICU, intensive care unit; ref, reference.
a Data are median (interquartile range) or n (% of all in the manifestation group).
b The crude measures are median ratios (95% CI) or prevalence proportion ratios (95% CI).
c The multiple adjusted relative risks are computed using linear regression for LOS, and Poisson regression for ICU admission and pulmonary complications.
The estimates are adjusted for age, sex, smoking, alcohol, and comorbidity.
d Pulmonary complications include pleural effusion, pleural drainage, empyema, and lung abscess.
Data available for over 99%.
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of in-hospital deaths (data not shown). Seven per cent of
no infiltrate and no bacteraemia patients were admitted
to the ICU during their hospitalization, compared to
20% and 23% among the other two groups. Pulmonary
complications occurred in 1% of patients with no infil-
trate and no bacteraemia, compared with 5% and 14%
among infiltrate without bacteraemia and bacteraemia
patients respectively (Table 4). After adjustment for sex,
age, comorbidity, smoking, and alcohol consumption,
adjusted RRs remained substantially increased for all ad-
verse outcomes among patients with an infiltrate with-
out bacteraemia and patients with bacteraemia, as
compared with the no infiltrate and no bacteraemia ref-
erence group.Supplementary analyses
To examine potential bias due to misclassification of in-
fection, four sensitivity analyses were made: (1) Because
the patient group without infiltrate and no bacteraemia
may have included people with chronic pulmonary dis-
ease who had pneumococci cultured in the absence of
any acute infection due to closer surveillance, we re-
peated our analyses with restriction to patients who all
had CRP >100mg/L or leukocytes >10*109/L together
with at least one new or increased pulmonary symptom.
This analysis yielded RRs very similar to those in the
main analysis (see Additional file 5). (2) We also ex-
cluded all patients with chronic pulmonary disease in
another analysis, resulting in LOS of 4 vs. 8 vs. 8 days;
ICU admission proportions of 8% vs. 29% vs. 23%; pul-
monary complications in 2% vs. 7% vs. 14%, and 30-day
mortalities of 3% vs. 12% vs. 20%. (3) Third, we
reanalysed data while excluding all patients who did not
have chest X-rays or blood cultures taken, which also
gave similar results as in the main analysis. (4) Finally,
we conducted an analysis restricted to patients who had
an ICD-10 discharge diagnosis of acute LRTI. This pro-
duced robust estimates (Additional file 5).Discussion
In this population-based cohort study, presence of a pul-
monary infiltrate was associated with a doubled 30-day
mortality from pneumococcal LRTI, whereas bacter-
aemia was associated with a four-fold increased mortal-
ity compared with patients with none of these clinical
manifestations. Differences in age, comorbidity and life-
style factors seemed to explain only a minor part of the
associations. LOS, risk of ICU admission, and risk of
pulmonary complications also rose gradually from pa-
tients with no infiltrate and no bacteraemia to those
with an infiltrate without bacteraemia and to those with
bacteraemia. Non-bacteraemia patients had more acute
LRTI symptoms compared to bacteraemia patients,
whereas other markers of disease severity (including
CRP, leukocyte count, fever, and CURB65 score) grad-
ually increased from patients with no infiltrate and no
bacteraemia to those with an infiltrate without bacter-
aemia to those with detected bacteraemia.
Biological mechanisms underlying the poorer outcome
among patients with X-ray changes and bacteraemia
may include hypoxaemia due to thickening of the blood-
gas barrier and loss of functional residual capacity in the
lungs, and increased risk of severe sepsis with decreased
perfusion of vital organs. Inflammatory exudate filling
alveoli during pneumonia causes a volume loss that im-
pact on lung capacity roughly proportional to the extent
of the pulmonary infiltrate [35]. A study of 48 pneumo-
nia patients from Japan found a significant correlation
between the size of X-ray pneumonic infiltrates and Pa02
both in young and elderly patients [16]. Hagaman et al.
[20] suggested the magnitude of the inflammatory re-
sponse in the lung tissue to be the most important de-
terminant whether a patient presents with a pulmonary
infiltrate or not. Both Hagaman et al. and Basi et al.
[19,20] found lower leukocyte counts for patients with
negative chest X-rays, corroborating our results. Our
findings that additional inclusion of CRP, leukocyte
count, MAP and SAT in the regression model reduced
the MRRs for both infiltrate without bacteraemia and
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mortality associated with these manifestations is medi-
ated through increased inflammation, hypoxaemia and
sepsis.
In the American PORT study based on 2,287 in- and
out- patients with CAP of whom 158 had confirmed
pneumococcal pneumonia, Brandenburg et al. [17] also
noted a tendency towards greater clinical severity for
bacteraemic compared with non-bacteraemic patients, as
reflected by increased median LOS (7.5 days vs. 6.5
days), pneumonia-related 30-day-mortality (7.7% vs.
2.7%), and ICU admission (15.4% vs. 12.2%) (p-values
between 0.4-0.8). In line with this, Musher et al. [10]
found bacteraemia to be indicative of a higher 30-day
mortality (21 vs. 13%; OR 1.88, p-value 0.25) and higher
ICU admission risk (44 vs. 25%; OR 2.38, p-value 0.05)
among 100 American veteran patients with pneumococ-
cal pneumonia. Likewise, a Spanish study comprising 57
bacteraemic and 25 non-bacteraemic hospitalized pneu-
mococcal CAP patients found a higher mortality and
LOS among bacteraemic patients [18]. In contrast, a
South African ICU-study of 63 severe pneumococcal
CAP patients found lower in-hospital mortality in bac-
teraemic compared to non-bacteraemic patients (15% vs.
28%) [14]. In comparison, a sub-analysis of our ICU pa-
tients showed a 30-day mortality of 29, 33 and 42% for
patients with no infiltrate and no bacteraemia, infiltrate
without bacteraemia, and bacteraemia, respectively.
To our knowledge no previous studies have focused
on outcomes of pneumococcal LRTI without bacter-
aemia or pulmonary infiltrate, but studies on unspecified
“clinical pneumonia” or “infiltrate-negative all-cause CAP”
have been conducted. In a population-based Canadian
study of 2706 hospitalised patients Basi et al. [19] reported
that approximately one-third of patients suspected of
CAP on admission did not have an infiltrate on their ad-
mission chest X-ray. The in-hospital mortality was 10% in
patients with X-ray confirmed pneumonia compared with
8% in patients without an infiltrate (p=0.09). In a smaller
American study of CAP, Hagaman et al. [20] found that
patients with presence of an infiltrate stayed one day lon-
ger and had slightly higher Pneumonia Severity Index
scores and mortality than those with no infiltrate. Similar
to our study, Hagaman et al. and Basi et al. did not find
any clear association between the amount of pulmonary
symptoms and chest X-ray findings.
Our study’s strengths include its relatively large size
covering one-third of the Danish population for one
year, its population-based design including all hospitals
in a geographical region, complete follow-up for mortal-
ity, and detailed information on blood chemistry, life-
style factors, and microbiology data for all patients, thus
allowing for extensive adjustment for important con-
founders and investigation of mediators. Use of routinelyrecorded health care data, collected without knowledge
of our research aim, reduced the risk of information
bias.
Our study was limited by lack of information on the
indication for collecting the blood or LRT specimen.
The no infiltrate and no bacteraemia patient group may
thus have included people with chronic LRTI or other
pulmonary diseases who had pneumococci cultured e.g.
as part of a diagnostic process in the absence of any
acute infection, resulting in an overestimation of the
relative risk of adverse outcomes in the other groups.
However, all patients in our no infiltrate and no bacter-
aemia group had to have at least one new or increased
pulmonary symptom together with CRP >50mg/L and/
or leukocytes >8.8*109/L, and our sensitivity analysis
using even stricter CRP and leukocyte cut points showed
robust results.
The validity of our estimates depends on S. pneumoniae
being the causative agent, as well as on accurate division
into manifestation groups based of chest X-ray findings
and blood cultures. For the purpose of this study we in-
cluded patients with chest X-rays describing a “likely” or
“probable” infiltrate in the infiltrate without bacteraemia
or bacteraemia groups. Assuming that patients with a
likely infiltrate are less ill than patients with a definite in-
filtrate, any misclassification is unlikely to create a false
difference between the infiltrate and no infiltrate patient
groups, and would not change our conclusions. Results of
sputum culture may be falsely positive due to upper air-
way colonization with pneumococci [36-38]. Nevertheless,
colonization is more common in young children and pa-
tients with chronic pulmonary disease, and excluding the
latter group did not alter our risk estimates notably.
Because the study was done in a routine clinical set-
ting, microbiology tests and chest X-rays were only
obtained at the managing physician’s discretion. Thus,
not all patients had all tests done. Some patients in the
two non-bacteraemic groups might have had bacter-
aemia, and some patients in the no-infiltrate group
might have had an infiltrate without our knowledge.
However, this would likely lead to bias towards the null,
and our sub-analysis excluding patients with no X-ray
or blood culture taken did not change our findings
markedly.
Conclusions
With the above limitations in mind our study demon-
strates that hospitalization with pneumococcal LRTI is a
severe disease even without presence of pulmonary infil-
trate or bacteraemia.
Still, there is a substantial and clinically important out-
come gradient from LRTI patients with pneumococcal
isolation only to those with concomitant pneumonia and
bacteraemia, which is at least in part mediated by higher
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coccal culture results are not usually available at time of
admission and thus not suitable for initial clinical
decision-making, the results of the present study may fos-
ter our understanding of disease mechanisms and the clin-
ical course of pneumococcal disease. Positive chest X-ray
findings add important prognostic information, and a
positive blood culture predicts substantially increased
mortality, higher risk of ICU admissions and pulmonary
complications, and longer length of stay.
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Additional file 1: Flowchart. A detailed chart review was done for
1,169 episodes of pneumococcal isolation from the blood and/or lower
respiratory tract in patients 15 years or older. Patients were excluded if
they did not comply with our predefined study criteria. Thus the final
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LRTI. LRT, lower respiratory tract; LRTI, lower respiratory tract infection;
CRP, C-reactive protein.
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Additional file 5: Outcomes according to LRTI manifestation group
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